Cargando…
Tuberculosis of the eye, case series study
Tuberculosis of the eye represents a challenge throughout the world, and there is a continuous debate about its pathophysiology, diagnosis, and treatment. The present research represents an interventional prospective study focusing on the variable clinical presentations, and the diagnostic and thera...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Carol Davila University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514815/ https://www.ncbi.nlm.nih.gov/pubmed/36188648 http://dx.doi.org/10.25122/jml-2021-0343 |
_version_ | 1784798351668019200 |
---|---|
author | Abd, Zeena Adnan |
author_facet | Abd, Zeena Adnan |
author_sort | Abd, Zeena Adnan |
collection | PubMed |
description | Tuberculosis of the eye represents a challenge throughout the world, and there is a continuous debate about its pathophysiology, diagnosis, and treatment. The present research represents an interventional prospective study focusing on the variable clinical presentations, and the diagnostic and therapeutic characteristics of ocular tuberculosis. Fifteen eyes from nine cases were diagnosed with ocular tuberculosis, treated, and followed up between 2010 and 2020. The diagnosis was based on (1) a compatible clinical picture, (2) highly positive Tuberculin skin test or a positive IGRA test (Interferon-Gamma Release Assays), (3) a dramatic response to anti-tuberculous drugs without systemic steroid. Mean age was 41.22±13.64 years; eight cases were females 89.8%, one male 11.1%. Only one case had preexisting pulmonary tuberculosis. Bilateral ocular involvement occurred in two thirds of cases (66.7%). The most common clinical presentation was intermediate uveitis (33.3%), followed by multifocal choroiditis (20%). All cases were cured without relapse for the 2–10 years of follow-up, after taking oral anti-tuberculous drugs for 6–12 months. No systemic steroids were given, only topical steroid drops, as indicated. In conclusion, ocular tuberculosis is a mysterious condition with a wide-range of clinical presentations and should be considered in the differential diagnoses of any type of intraocular inflammation, or any unexplained reduction in vision. Oral anti-tuberculous drugs with or without topical steroids are sufficient to improve vision, produce, cure, and prevent relapse. |
format | Online Article Text |
id | pubmed-9514815 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Carol Davila University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95148152022-10-01 Tuberculosis of the eye, case series study Abd, Zeena Adnan J Med Life Original Article Tuberculosis of the eye represents a challenge throughout the world, and there is a continuous debate about its pathophysiology, diagnosis, and treatment. The present research represents an interventional prospective study focusing on the variable clinical presentations, and the diagnostic and therapeutic characteristics of ocular tuberculosis. Fifteen eyes from nine cases were diagnosed with ocular tuberculosis, treated, and followed up between 2010 and 2020. The diagnosis was based on (1) a compatible clinical picture, (2) highly positive Tuberculin skin test or a positive IGRA test (Interferon-Gamma Release Assays), (3) a dramatic response to anti-tuberculous drugs without systemic steroid. Mean age was 41.22±13.64 years; eight cases were females 89.8%, one male 11.1%. Only one case had preexisting pulmonary tuberculosis. Bilateral ocular involvement occurred in two thirds of cases (66.7%). The most common clinical presentation was intermediate uveitis (33.3%), followed by multifocal choroiditis (20%). All cases were cured without relapse for the 2–10 years of follow-up, after taking oral anti-tuberculous drugs for 6–12 months. No systemic steroids were given, only topical steroid drops, as indicated. In conclusion, ocular tuberculosis is a mysterious condition with a wide-range of clinical presentations and should be considered in the differential diagnoses of any type of intraocular inflammation, or any unexplained reduction in vision. Oral anti-tuberculous drugs with or without topical steroids are sufficient to improve vision, produce, cure, and prevent relapse. Carol Davila University Press 2022-08 /pmc/articles/PMC9514815/ /pubmed/36188648 http://dx.doi.org/10.25122/jml-2021-0343 Text en ©2022 JOURNAL of MEDICINE and LIFE https://creativecommons.org/licenses/by/3.0/This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Original Article Abd, Zeena Adnan Tuberculosis of the eye, case series study |
title | Tuberculosis of the eye, case series study |
title_full | Tuberculosis of the eye, case series study |
title_fullStr | Tuberculosis of the eye, case series study |
title_full_unstemmed | Tuberculosis of the eye, case series study |
title_short | Tuberculosis of the eye, case series study |
title_sort | tuberculosis of the eye, case series study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514815/ https://www.ncbi.nlm.nih.gov/pubmed/36188648 http://dx.doi.org/10.25122/jml-2021-0343 |
work_keys_str_mv | AT abdzeenaadnan tuberculosisoftheeyecaseseriesstudy |